Drugs / Moxtezafin Gadolinium
last change May 2015 re-read 2 minutes ago

Moxtezafin Gadolinium

Developed for
B-cell non-Hodgkin lymphoma
Investigated by
Spectrum Pharmaceuticals, Inc

Trials 1 · a red edge is where a trial was stopped

2012201320142015201620172018201920202021202220232024202520262027
PhaseRegistry idDatesIndicationSponsorStatusOutcome
Phase 2 NCT01549886 Nov 2011 → Jun 2014 B-cell non-Hodgkin lymphoma Spectrum Pharmaceuticals, Inc Terminated No outcome recorded

Evidence & citations 1 cited value

Every value below carries the sentence it was read from. 1 source stands behind the page.

FieldValueCited text
Known as Moxtezafin Gadolinium ClinicalTrials.gov intervention name — accepted as the source's own label NCT01549886